Tiziana Life Sciences hails positive results from Brazil coronavirus study of breakthrough nasally-a

0 93

Tiziana Life Sciences PLC (NASDAQ:TLSA)  (LON:TILS) has delivered positive data from a clinical trial of its nasally-delivered monoclonal antibody in people affected by coronavirus (COVID-19).

It said that in the groups receiving the drug, there was a significant improvement in lung function as well as major reductions in Interleukin-6 and c-reactive protein, which are both indicative of inflammation.

Tiziana’s Foralumab was administered on its own and with dexamethasone, a corticosteroid, and the results were compared with a control group. The data can be seen below:

The fully human anti-CD3 monoclonal antibody (mAB) proved to be safe in the group of 39 patients that were assessed by a team that included researchers from the prestigious Harvard Medical School.

In a statement, lead scientist Dr Thais Moreira said: “We are delighted to see that patients treated with nasally administered Foralumab showed a positive trend in the reduction of lung inflammation, and supportive data indicating significant reduction in cytokine IL-6 and C-reactive protein.

“In addition, there are indications from patients who reported that treatment with Foralumab rapidly improved the smell and taste sensations that are frequently lost with the severity of COVID-19 disease”.

Nasally-administered Foralumab is thought to work by improving the immune system by stimulating the body’s regulatory T cells.

It is also believed to dampen cytotoxic (harmful) T cell responses in the nasal and respiratory tract, the primary sites of the COVID-19 virus.

As such, Tiziana’s scientists think Foralumab may be effective in treating new coronavirus variants from the UK, Brazil and South Africa because it does not attack the disease directly but modulates its effects on the immune system.

The Tiziana breakthrough is the first monoclonal antibody that can be dosed nasally or orally due to its ability to affect systemic immunity via the epithelial lining of the nose, respiratory tract and gut.

This marks it out as different to mAB innovations such as Sorrento Therapeutics’ (NASDAQ:SRNE) COVID-19 treatment, which is directly injected.

Tiziana chief executive, Dr. Kunwar Shailubhai commented: “This is a first-in-class and scientifically logical approach to modulate the host immune system to fight the inflammatory reaction to SARS-CoV2 (Covid-19 virus).

“Thus, this approach may be effective against patients infected with the newly identified Covid-19 variants in UK, South Africa and Brazil, but there is no data on this yet.”

Separately, shares in BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) raced past their five-year high on Monday as Reddit investors weighed in on them.

Their call was to start a “#BioWar” on the bears behind a heavily-shorted the group, which is developing an experimental therapy for COVID-19.

One poster on Reddit’s WallStreetBets forum called it “the most undervalued stock in the market” while another said a brewing #BioWar was “about sticking it to the shorts in a massive way”.

 

Leave A Reply

Your email address will not be published.